This content is not available in your region

AstraZeneca to distribute Sun Pharma cancer drugs in China

Access to the comments Comments
AstraZeneca to distribute Sun Pharma cancer drugs in China
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo   -   Copyright  Brendan McDermid(Reuters)
Text size Aa Aa

BENGALURU (Reuters) – Indian drugmaker Sun Pharmaceutical Industries Ltd <SUN.NS> said on Wednesday it would introduce some of its cancer treatment drugs in China through Britain’s AstraZeneca <AZN.L>.

This comes after AstraZeneca said it was launching a new fund with China International Capital Corp to invest $1 billion in China’s healthcare sector, as it expands its research work in the country.

Sun Pharma will be responsible for development, regulatory filings and manufacturing of the drugs covered in the deal, while AstraZeneca will exclusively promote and distribute the products in China, according to a filing to Indian stock exchanges.

The financial terms of the agreement, which has an initial tenure of 10 years, were not disclosed.

(Reporting by Chris Thomas in Bengaluru; Editing by Subhranshu Sahu)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.